Insider · CIK 0001543663
Christine Mikail Cvijic
cfopresidentofficer
Files at NGNE (Neurogene Inc.). First filing Nov 25, 2024, latest Mar 30, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 1
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 4
$491k bought, $336k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NGNE: Neurogene Inc.
NGNEOct 9, 2026 · close 26.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | Neurogene Inc. | $55k 2,558 shares | -2% | +192% from low-38% from high | |
| 19Weak | Neurogene Inc. | $84k 4,045 shares | -4% | +193% from low-37% from high | |
| 20Weak | Neurogene Inc. | $121k 4,800 shares | -4% | +220% from low-32% from high | |
| 10Weak | Neurogene Inc. | $76k 4,501 shares | -6% | +12% from low-77% from high | |
| 61Notable | Neurogene Inc. | $491k 24,000 shares | +45% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -2,558 | $21.62 | $55k | 103,240 | Mar 30, 2026 |
| Mar 13, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -2,387 | $20.42 | $49k | 107,456 | Mar 17, 2026 |
| Mar 13, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -1,395 | $21.25 | $30k | 106,061 | Mar 17, 2026 |
| Mar 13, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -263 | $22.02 | $5,791 | 105,798 | Mar 17, 2026 |
| Feb 27, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -4,800 | $25.11 | $121k | 109,843 | Mar 3, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Common Stock | +22,000 | $0.00 | $0 | 114,643 | Feb 24, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Stock Option (Right to Buy)derivative | +131,900 | $0.00 | $0 | 131,900 | Feb 24, 2026 |
| Mar 26, 2025 | NGNE Neurogene Inc. | AGrant or award Common Stock | +20,300 | $0.00 | $0 | 92,643 | Mar 28, 2025 |
| Mar 26, 2025 | NGNE Neurogene Inc. | AGrant or award Employee Stock Option (Right to buy)derivative | +122,000 | $0.00 | $0 | 122,000 | Mar 28, 2025 |
| Mar 13, 2025 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -4,501 | $16.94 | $76k | 72,343 | Mar 17, 2025 |
| Nov 22, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stock | +24,000 | $20.48 | $491k | 76,844 | Nov 25, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.